ACADIA Pharmaceuticals (ACADIA Pharmaceuticals) Change In Inventory : $-28.8 Mil (TTM As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is ACADIA Pharmaceuticals Change In Inventory?

ACADIA Pharmaceuticals's change in inventory for the quarter that ended in Dec. 2023 was $-15.1 Mil. It means ACADIA Pharmaceuticals's inventory increased by $15.1 Mil from Sep. 2023 to Dec. 2023 .

ACADIA Pharmaceuticals's change in inventory for the fiscal year that ended in Dec. 2023 was $-28.8 Mil. It means ACADIA Pharmaceuticals's inventory increased by $28.8 Mil from Dec. 2022 to Dec. 2023 .

ACADIA Pharmaceuticals's Total Inventories for the quarter that ended in Dec. 2023 was $35.8 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. ACADIA Pharmaceuticals's Days Inventory for the quarter that ended in Dec. 2023 was 144.31.

Inventory Turnover measures how fast the company turns over its inventory within a year. ACADIA Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.63.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. ACADIA Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.12.

ACADIA Pharmaceuticals Change In Inventory Historical Data

The historical data trend for ACADIA Pharmaceuticals's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ACADIA Pharmaceuticals Change In Inventory Chart

ACADIA Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Get a 7-Day Free Trial

-1.74

-3.32

-4.21

2.42

-28.81

ACADIA Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Inventory	Get a 7-Day Free Trial															0.31	0.48	-3.00	-11.22	-15.07

ACADIA Pharmaceuticals Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-28.8 Mil.

ACADIA Pharmaceuticals (NAS:ACAD) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

ACADIA Pharmaceuticals's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	28.2935	/	17.891	*	365 / 4
	=	144.31

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

ACADIA Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	17.891	/	28.2935
	=	0.63

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

ACADIA Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	28.2935	/	231.041
	=	0.12

ACADIA Pharmaceuticals Change In Inventory Related Terms

Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

ACADIA Pharmaceuticals (ACADIA Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (NAS:ACAD) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

DR6:Germany DR6:Germany

Address

12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130

Website

https://www.acadia-pharm.com

Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Executives

Austin D. Kim	officer: EVP & General Counsel	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Brendan Teehan	officer: EVP, COO, Head of Commercial	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Stephen Davis	director, officer: PRESIDENT AND CEO	ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
James Kihara	officer: Principal Accounting Officer	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Mark C. Schneyer	officer: Chief Financial Officer	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Laura Brege	director	C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Baker Bros. Advisors Lp	10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Douglas J Williamson	officer: Executive VP, Research & Dev	AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN L2 D02 T390
Srdjan R. Stankovic	officer: EVP	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Adora Ndu	director	C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Elena Ridloff	officer: EVP and CFO	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Michael J. Yang	officer: EVP AND CCO	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Elizabeth A. Garofalo	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
James M Daly	director	INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880
Eric Alejandro Miller	officer: Controller & PAO	C/O ACADIA PHARMACEUTICALS INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130